Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Prospective Study Evaluating the Rate of Inhibitor Recurrence Following Successful ITI in Patients Receiving Ongoing Once Per Weekly Factor VIII Therapy Along With Emicizumab and in Patients Who Discontinue FVIII Therapy and Are on Emicizumab for Prophylaxis

NCT04621916 is registered in ClinicalTrials.gov with Children's Hospital Los Angeles as lead sponsor.

NCT NCT04621916
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04621916 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Prospective Study Evaluating the Rate of Inhibitor Recurrence Following Successful ITI in Patients Receiving Ongoing Once Per Weekly Factor VIII Therapy Along With Emicizumab and in Patients Who Discontinue FVIII Therapy and Are on Emicizumab for Prophylaxis
Lead sponsor
Children's Hospital Los Angeles
Phase
Phase 4
Overall status
Unknown status
Start date
September 21, 2020
Completion date
April 20, 2025
Enrollment
52 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

hemophilia a, immune tolerance